Connect with us

Industry

UK Government ‘could tear up EU rules on hemp’ in boost to CBD industry

The UK Government is reportedly considering handing a huge boost to the CBD industry by reforming hemp harvesting rules.

Published

on

Only a small part of the hemp plant can be used to harvest CBD oil under the law - but that could be set to change

The UK Government is reportedly considering handing a huge boost to the CBD industry by reforming hemp harvesting rules.

At present it is legal to derive the valuable oil from stalks and seeds but the flowers and leaves of the hemp plant must be destroyed under pre-Brexit rules carried over from EU law.

But ministers could be planning to tear up the regulations following a report by drugs reform group Volteface, The Telegraph reports.

The Government is facing increasing calls from within the Conservative party to free up an industry already worth £300m in the UK and projected to grow rapidly.

Britain imports large quantities of CBD oil and raw material for production, despite the fact it could be produced cheaply and effectively domestically.

The leaves and flowers of the hemp plant are still controlled under the Misuse of Drugs Act even though they possess no psychoactive properties.

Environment minister Victoria Prentis confirmed to the newspaper that her department will be ‘commissioning a project not he potential use of under-utilised, underdeveloped or novel crops, including hemp’.

She added: “We are also considering the role of hemp in the bioeconomy and the opportunities this presents for UK farmers.”

Supporters of a change in regulations within the Tory party include former leader Iain Duncan Smith and former Transport Minister, George Freeman, the Telegraph reports.

Mr Freeman told the newspaper: “We could have an industrial hemp industry that would be good for British farming and agriculture, we would not rely on imports so much to develop these products and that would be good for the balance of trade.”

READ MORE  How to use CBD to tackle back pain

Industry

Grow Pharma launches new platform to help UK doctors learn about medical cannabis

The Journal Club will help inform UK doctors about the latest medical cannabis research.

Published

on

Doctor
A new platform help inform doctors about the latest medical cannabis research.

Grow Pharma has launched a Journal Club to help inform UK doctors about the latest medical cannabis research.

The UK’s leading distributor of prescribed cannabis medicines, Grow Pharma, is now launching the latest in a string of initiatives aimed at educating doctors on cannabis medicines.

Each edition of the Journal Club will feature two recently published clinical papers relevant to the field of medical cannabis/cannabinoids from a variety of different disease areas including chronic pain, psychiatric disorders, neurology, and IBD, and will be released approximately every two weeks.

Those interested can sign up to Grow’s Journal Club here.

Grow Pharma: Journal Club

The first Journal Club will be sent round on 1st December featuring the articles named here.

The clinical papers will be emailed out as well as hosted on Grow’s Doctor Portal where healthcare professionals will be able to comment on the articles and share thoughts and ideas with each other. The Doctor Portal also features recordings of past webinar educational sessions from medical cannabis experts, as well as news articles, information on medicines and discussion forums for doctors.

Grow Pharma: Dr Portal

Doctors can sign up to the Grow Doctor Portal here


“Educating doctors really is the key to increasing the use and acceptance of medical cannabis in the UK,” commented Grow Pharma CEO, Pierre Van Weperen.

“We have had significant success in supporting new doctors on their journey towards prescribing medical cannabis. Many doctors want to be involved in multiple educational sessions and hear from others who are already prescribing. We facilitate those interactions. We also help to connect them to existing specialist cannabis clinics or help them set up their own clinics.”

Grow Pharma

Grow Pharma CEO Pierre Van Weperen leads the team in educating healthcare professionals on cannabis medicines

There are now upwards of 15 clinics specialising in the prescription of cannabis medicines in the UK and on the Channel Islands.

Grow Pharma are proud to be the preferred distributor for more of these clinics than any other and is dedicated to supporting the clinics and doctors as they learn about medical cannabis, onboard new doctors and set themselves up as centres of expertise in the field. Grow puts its success down to having the broadest range of cannabis medicines available in the UK and their hard work and dedication to supporting doctors throughout the process.

The clinical papers featured in the Journal Club will be selected by Grow’s Medical Team for their high level of evidence and relevance to clinical areas where there is the most perceived potential to help patients.

In the UK, any specialist doctor can prescribe cannabis medicines within their field but not all doctors are aware of the potential benefits of cannabis medicines, even three years after they were rescheduled, due to a lack of formal education from clinical bodies. Grow Pharma believes that the Journal Club will help to bridge this gap in doctors’ knowledge.

Grow Pharma clinic list

There are now over 15 clinics specialising in prescribing cannabis medicines in the UK for patients to choose from.

“We all know how busy UK doctors are. It’s understandable they don’t always have the time to read about new treatments, especially one like medical cannabis, where there is so much to learn about the many ways it can help patients,” said Grow’s patient access lead Alex Fraser.

“The Journal Club is about making it easy and straightforward for Doctors to keep up-to-date with research and to continue learning about cannabis medicines, even if they are already prescribing them. We carefully select the studies and deliver them straight to their inbox in digestible chunks.

“If they have any more questions, they know that we’re on hand to answer them.”

Whilst the Doctor Portal is only accessible to healthcare professionals and the Journal Club is aimed at doctors, anyone can sign-up if they want to learn more about medical cannabis. The Journal Club is educational and non-promotional and solely designed to increase awareness of the latest research around this exciting field of medicine.

To sign up to Journal Club just click the link and fill in the short form here

Hippie Turtle: A banner advertising collaborative content

READ MORE  Nike launches exclusive hemp trainer
Continue Reading

Industry

Study: States with full legal access show fewer registered medical cannabis patients

“If true, this could have implications for public health and policy,” say researchers.

Published

on

Study shows U.S states where cannabis is legal for recreational purposes have experienced a decrease in patients registering for medical cannabis programmes.

The study on different US states, published in the International Drug Journal, revealed that numbers of registered and active medical cannabis consumers increased while it was not legal for recreational use.

Researchers in Arizona took data from the medical cannabis registry from two dozen states between 2013 and 2020.  These are mandatory registries that record the number of medical cannabis patients. They analysed the data to see if there were any changes around the times that recreational legalisation was introduced.

There are currently 19 states in the US that have legalised recreational cannabis including New Jersey, Vermont, Arizona and New York. However, more states have medical cannabis programs although some are still not operational. Some states such as Colorado have had recreational access since 2012, the year before the study was started.

Medical cannabis patients

The results confirmed that medical cannabis cardholders increased during times when recreational use was not legal. It then subsequently decreased when it became legal.

It also revealed an increase of 380 patients per 100,000 people per year when just medical cannabis was legal. This corresponded to a decrease of 100 patients per 100,000 after recreational cannabis was allowed. The researchers noted that active registered active male patients decreased faster than women. In states where only medical cannabis was legal, the older age groups (35 or older), increased faster.

They also found that in three states with medical-only use, the results showed significant increases in enrollment from 2016 to 2020 across white, African-American and Hispanic patients.

READ MORE  Calls for cannabis medicines to be added to NHS drug dictionary

The researchers wrote: “There is speculation that enrollment in U.S. state medical cannabis programs differs depending on whether adult recreational cannabis use is legal. If true, this could have implications for public health and policy.”

“Findings suggest that recreational cannabis legalisation is associated with decreasing enrollment in medical cannabis programs, particularly for males.”

Medical Cannabis: A banner advert for subscribing to cannabis health

Continue Reading

Industry

Latin American cannabis clinic Zerenia arrives in UK – promising patients more ‘affordable’ access

The clinic has recently joined Project Twenty21 with the promise of making medical cannabis more accessible.

Published

on

Zerenia clinic: doctor holding medical cannabis
The clinic will initially prescribe for chronic pain and mental health conditions.

Latin American medical cannabis clinic, Zerenia, has launched in the UK, with a bid to improve patient access as it joins Project Twenty21.

Zerenia Clinics, which launched in the UK in recent weeks, has joined a growing number of clinics on Project Twenty21 (T21), as it aims to make medical cannabis more affordable for patients. 

The clinic also offers competitive costs, with consultation fees at £80. 

The clinic’s three doctors will initially prescribe for chronic pain and mental health, with the majority of patients so far seeking treatment for indications such as anxiety, ADHD, PTSD and insomnia.

Zerenia, which already has 14 clinics across Latin America, has treated around 14,000 patients with medical cannabis, and according to Zerenia’s UK clinical operations director, Freeda Solliman, mental health is the predominant indication prescribed for. 

Many of these patients now get their prescriptions funded via private insurers, a model which the clinic now hopes to replicate in the UK. 

“In Latin America we’ve built a body of evidence there to support private insurers to fund medical cannabis treatment,” Solliman told Cannabis Health.

“We’ve seen about 14,000 patients who have been treated with medical cannabis and a large number of those actually get their prescriptions funded by private insurers. That’s the kind of model that you want to bring here.”

Zerenia has partnered with T21, which subsidises the cost of prescriptions, to help build the growing body of evidence for the safety and efficacy of medical cannabis. 

“Our goals are quite well aligned, we want to build the evidence and we want to make medical cannabis more affordable for patients,” continued Solliman.

“We want to work to encourage the NHS first and foremost, but also private insurers to fund at least part of the costs involved in being treated with medical cannabis.”

She added: “We did our research to understand some of the bottlenecks in the industry and how hard it is for some patients to go through the process, so we wanted to support patients through that and try to offer them more of a seamless experience.”

Zerenia is now taking on new patients who wish to join T21, or those who may want to try a different clinic. 

Initial consultations for new patients are priced at £80, for those transfering from a different clinic, £40. Find more information here

READ MORE  Cannabis both 'helps and hurts' creativity - study
Continue Reading

Trending